Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) EBITDA Margin (2020 - 2025)

Pliant Therapeutics (PLRX) has disclosed EBITDA Margin for 5 consecutive years, with 17372.06% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 17372.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 5849.16%, a N/A change, with the full-year FY2023 number at 10065.38%, down 877392.0% from a year prior.
  • EBITDA Margin was 17372.06% for Q4 2025 at Pliant Therapeutics, up from 3222.82% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 17372.06% in Q4 2025 to a low of 16976.61% in Q2 2023.
  • A 4-year average of 85.79% and a median of 1256.04% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: soared 67844bps in 2022, then tumbled -1637820bps in 2023.
  • Pliant Therapeutics' EBITDA Margin stood at 1235.22% in 2021, then plummeted by -42bps to 1758.98% in 2022, then plummeted by -865bps to 16976.61% in 2023, then skyrocketed by 202bps to 17372.06% in 2025.
  • Per Business Quant, the three most recent readings for PLRX's EBITDA Margin are 17372.06% (Q4 2025), 3222.82% (Q3 2025), and 5372.06% (Q2 2025).